Prelude Therapeutics IncorporatedPrelude Therapeutics IncorporatedPrelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

No trades
See on Supercharts

Price target

5.400.000.00%
The 5 analysts offering 1 year price forecasts for PRLD have a max estimate of — and a min estimate of —.

Analyst rating

Based on 5 analysts giving stock ratings to PRLD in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


PRLD EPS for the last quarter is −0.43 USD despite the estimation of −0.47 USD. In the next quarter EPS is expected to reach −0.47 USD. Track more of Prelude Therapeutics Incorporated financials and stay on top of what is up with the company.
In the next quarter Prelude Therapeutics Incorporated revenue is expected to reach 0.00 USD. Check out Prelude Therapeutics Incorporated revenue and earnings and make informed decisions.
According to analysts, PRLD price target is 5.40 USD with a max estimate of 10.00 USD and a min estimate of 1.00 USD. Check if this forecast comes true in a year, meanwhile watch Prelude Therapeutics Incorporated stock price chart and keep track of the current situation with PRLD news and stock market news.
We've gathered opinions of 5 analysts rating PRLD stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as neutral. Note that it's not a trading advice — your own analysis is still required.